Lead Product(s) : TTX-MC138
Therapeutic Area : Oncology
Study Phase : Phase I/II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TransCode Treats First Patients in Phase 1 Trial of First-in-Class Candidate
Details : TTX-MC138 is an antisense oligonucleotide that targets microRNA-10b, it is designed to inhibit microRNA-10b. It is being evaluated for advanced solid tumors.
Brand Name : TTX-MC138
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 17, 2024
Lead Product(s) : TTX-MC138
Therapeutic Area : Oncology
Highest Development Status : Phase I/II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?